Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Warns Of Bigger Negative Impact From COVID-19 And Biosimilars

Executive Summary

Biosimilar competitors to Avastin, Herceptin and Rituxan and headwinds from COVID-19 are expected to have a CHF4.7bn negative impact in 2020, higher than the CHF4bn previously projected.

You may also be interested in...



Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology

Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy.

US Biosimilar Spending Poised For Substantial Growth By 2024, IQVIA Says

Biosimilar spending in the US is expected to increase from $5.2bn in 2019 to $27bn in 2024, driven by increased penetration and new biosimilar entries, including for Humira, according to an IQVIA report.

Stockwatch: Full-Year 2020 Guidance Separates Novartis And Roche

Pandemic-related clinic closures and safety issues forced Novartis to trim its guidance slightly. But Roche, faced with more severe pandemic and biosimilar pressures, left January’s guidance unchanged.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC142644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel